Literature DB >> 15450778

HIV-1 clade-C-associated "ALS"-like disorder: first report from India.

Sanjib Sinha1, Thomas Mathews, G R Arunodaya, Nagadenahalli B Siddappa, Udaykumar Ranga, A Desai, V Ravi, A B Taly.   

Abstract

A patient of ALS-like disorder in an HIV-1 clade-C-infected heterosexual male is being reported. A 37-year-old gentleman presented with subacute, progressive asymmetrical onset of weakness and wasting of upper limbs associated with brisk muscle stretch reflexes and without any sensory or sphincter involvement. While nerve conduction tests were normal, the EMG of proximal and distal limb muscles on both sides revealed evidence of denervation and reinnervation. Routine blood and urine tests and investigations for underlying causes of motor neuron disease were noncontributory. He was HIV-1, subtype clade C seropositive. A diagnosis of HIV-related anterior horn cell disease was considered and zidovudine, lamivudine and nevirapine were started. After 1 month, there was a subjective improvement of 10% and objective improvement in strength of muscles of proximal upper limb on both sides by one grade power on MRC scale. Reports of amyotrophic lateral sclerosis (ALS)-like illness in HIV are sparse. The reversibility of "ALS"-like features in this subgroup of patients might offer an insight into the pathogenesis of amyotrophic lateral sclerosis. This is a first report of ALS-like illness caused by subtype C of HIV-1 strain.

Entities:  

Mesh:

Year:  2004        PMID: 15450778     DOI: 10.1016/j.jns.2004.06.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Mice deficient in the ALS2 gene exhibit lymphopenia and abnormal hematopietic function.

Authors:  Elizabeth A Erie; Hoon Shim; Aleah L Smith; Xian Lin; Keyvan Keyvanfar; Chengsong Xie; Jichun Chen; Huaibin Cai
Journal:  J Neuroimmunol       Date:  2006-12-06       Impact factor: 3.478

Review 2.  Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.

Authors:  Wenxue Li; Darshan Pandya; Nicholas Pasternack; Marta Garcia-Montojo; Lisa Henderson; Christine A Kozak; Avindra Nath
Journal:  Neurotherapeutics       Date:  2022-04-12       Impact factor: 6.088

Review 3.  Alsin and the molecular pathways of amyotrophic lateral sclerosis.

Authors:  Jayanth Chandran; Jinhui Ding; Huaibin Cai
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

4.  Flail arm-like syndrome associated with HIV-1 infection.

Authors:  A Nalini; Anita Desai; Simendra Kumar Mahato
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

Review 5.  Retroviruses and amyotrophic lateral sclerosis.

Authors:  Tariq Alfahad; Avindra Nath
Journal:  Antiviral Res       Date:  2013-05-23       Impact factor: 5.970

6.  Formation of multinucleated giant cells and microglial degeneration in rats expressing a mutant Cu/Zn superoxide dismutase gene.

Authors:  Sarah E Fendrick; Qing-Shan Xue; Wolfgang J Streit
Journal:  J Neuroinflammation       Date:  2007-02-28       Impact factor: 8.322

7.  Acute lower motor neuron syndrome and spinal cord gray matter hyperintensities in HIV infection.

Authors:  Isaac I Bogoch; Michael R Wilson; David A Chad; Nagagopal Venna
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-05-14

8.  Amyotrophic Lateral Sclerosis-like Syndrome after Chikungunya.

Authors:  Felipe César Andrade; Vinicius Vergetti; Gabriella Cozza; Maria Clara Falcao; Gustavo Azevedo
Journal:  Cureus       Date:  2019-10-09

9.  A rare syndromic presentation of HIV infection.

Authors:  Abhishek Juneja; Kuljeet Singh Anand; Brijlal Choudhary
Journal:  Indian J Sex Transm Dis AIDS       Date:  2020-07-31

10.  Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.

Authors:  Rebecca Banerjee; R Lee Mosley; Ashley D Reynolds; Alok Dhar; Vernice Jackson-Lewis; Paul H Gordon; Serge Przedborski; Howard E Gendelman
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.